Overactive Bladder Treatment Market Anticipated to Grow at 5.2% CAGR Through 2029: Industry Report

 Offering reliable and timely data, this report is a key resource for anyone building or refining their overactive bladder treatment industry roadmap.

 

 What Is The Expected CAGR For The Overactive Bladder Treatment Market Through 2025?
 The overactive bladder treatment market size has grown steadily in recent years. It will grow from $3.15 billion in 2024 to $3.24 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to medication development, patient awareness, demographic shifts, clinical guidelines, investment in research.
 
 The overactive bladder treatment market size is expected to see strong growth in the next few years. It will grow to $3.97 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging population, advanced therapies, personalized medicine, healthcare investments, patient-centric care. Major trends in the forecast period include non-pharmacological interventions, digital health solutions, alternative medicine acceptance, gender-specific approaches, and holistic care.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=9950&type=smp
 
 Which Key Factors Will Influence Overactive Bladder Treatment Market Growth Over 2025–2034?
 A rising geriatric population is expected to boost the growth of the overactive bladder treatment market going forward. The geriatric population refers to the population of people aged 65 and older. Geriatric patients are more vulnerable to urinary tract infections due to a variety of factors, such as decreased urine flow, an overactive bladder, an enlarged prostate, or kidney stones. This will propel demand for overactive bladder treatments. For instance, in July 2022, according to the ReliefWeb, a US-based humanitarian information portal, the global population of people aged 65 or older is expected to increase from 10% in 2022 to 16% in 2050. Further, this population is expected to grow to 94 million by 2050, accounting for 23% of the total population. Therefore, the rising geriatric population is driving the growth of the overactive bladder treatment market. 
 
 Comprehensive Segment-Wise Insights Into The Overactive Bladder Treatment Market
 The overactive bladder treatmentmarket covered in this report is segmented — 
 
 1) By Diseases Type: Idiopathic Bladder Overactivity; Neurogenic Bladder Overactivity
 2) By Therapy: Anticholinergics; Mirabegron; Neurostimulation; Intravesical Instillation; Other Therapies
 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
 
 Subsegments:
 1) By Idiopathic Bladder Overactivity: Urge Incontinence; Urgency Frequency 
 2) By Neurogenic Bladder Overactivity: Spinal Cord Injury-Related Overactivity; Multiple Sclerosis-Related Overactivity; Stroke-Related Overactivity 
 
 Key Trends Driving Growth In The Overactive Bladder Treatment Market
 Product approvals are a popular trend in the overactive bladder treatment market. Major companies operating in the market are developing advanced products integrated with the latest technologies to sustain their position in the market. For instance, in April 2023, Avation Medical Inc., a US-based advanced neuromodulation & digital health company, announced FDA clearance for The Vivally System. It is a wearable, non-invasive bladder control therapy device, and accompanying mobile application are used to treat patients suffering from urge urinary incontinence and urine urgency brought on by overactive bladder syndrome. The system combines a comfortable ankle-worn garment with an intelligent controller that delivers personalized neuromodulation energy to the tibial nerve. 
 
 Analysis Of Key Players In Overactive Bladder Treatment Market
 Major companies operating in the overactive bladder treatment market include AbbVie Inc., Astellas Pharma Inc., Laborie Medical Technologies Corporation, Endo International plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services Inc., Medtronic plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, Cogentix Medical Inc., Dr. Reddy’s Laboratories Ltd., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Merck & Co. Inc., Macleods Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Novartis International AG, Daiichi Sankyo Company ltd., Boston Scientific Corporation, Grünenthal GmbH, Collegium Pharmaceutical Inc. 
 
 View the full overactive bladder treatment market report here:
 https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report
 
 What Are The Key Regional Trends In The Overactive Bladder Treatment Market?
 North America was the largest region in the overactive bladder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the overactive bladder treatment market report during the forecast period. The regions covered in the overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company